Abstract
Pullulan-coated liposomes conjugated with monoclonal antibody (immunoliposomes) have been developed. The usefulness of the immunoliposomesencapsulated adriamycin (MoAb-Lipo [ADR]) was examined on targeting cancer chemotherapy in an animal model. The mouse monoclonal IgM antibody (CSLEX 1) by immunization with human stomach cancer was used. MoAb-Lipo [ADR] was compaired with pullulan-coated liposomesencapsulated adriamycin without CSLEX 1 antibody and ADR alone. There was no differences in cytotoxic activity in vitro against human lung cancer cell line (PC-9), reacting with CSLEX 1, among them. However, MoAb - Lipo [ADR] inhibited the growth of the implanted PC-9 tumor in vivo more strongly than the others. The ADR concentration in tumor was higher at 30 min to 8 hr after the administration in MoAb-Lipo [ADR] than in the others. In the heart, it was lower in liposomal ADR than in ADR alone, which was a significant benefit. These results demonstrated that MoAb-Lipo [ADR] was an ideal drug carrier on targeting cancer chemotherapy.
